Published
January 18, 2024

HRQOL

icon-benefit
HomeSubstudies
HRQOL

This substudy aims to describe the health-related quality of life (HRQOL) and long term community costs of Staphylococcus aureus bacteraemia in Aotearoa New Zealand, combining traditional HRQOL measures with data from the country's Integrated Data Infrastructure.

Substudies in Progress

SNAP Trial

CERT-SNAP

Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.

icon-benefit
All Interested
icon-benefit
Substudy in Progress

DAPTO-SNAP

Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

cfDNA

Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia

icon-benefit
Any interested
icon-benefit
Substudy in Progress

SABSI-Outcomes

Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

PR-O-SNAP

PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.

icon-benefit
New Zealand
icon-benefit
Substudy in Progress
BACK TO TOP